Clinical trials with various generations of ABC transporter inhibitors showed limited benefits to cancer patients due to inherent toxicity (first-generation ABC inhibitors), off-target effects, potential drug-drug interactions (second-generation ABC inhibitors), and narrow therapeutic range for targeted transporter inhibition (third-generation ABC inhibitors)[57,62]. The gene discussed is ABCB6; the disease is cancer.